Integrative Obesity and Cardiometabolic Care Explained

Explore integrative obesity and cardiometabolic care for improved health outcomes and overall wellness in your weight management journey.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this comprehensive educational post, I guide you through an easy-to-understand journey addressing obesity care across midlife, spanning ages 40 to 60, and the connected complexities of cardiometabolic syndrome, hepatic health (MASLD/MASH), sleep disorders (particularly obstructive sleep apnea), psychiatric and psychosocial dynamics, musculoskeletal pain, osteoarthritis, and menopausal transitions. I present the latest findings from leading researchers using modern, evidence-based methods, and I show how these data translate into practical, compassionate, integrative care.

Our multidisciplinary practice, Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, operates with a collaborative model common in integrative and injury clinics: I provide chiropractic, functional medicine, rehabilitation, and personal injury care, while our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), with more than 40 years of experience, leads medical oversight for diagnostics, medications, risk mitigation, and safety. Together, we co-manage complex obesity-related conditions with an approach that unifies structural care, autonomic balance, cardiometabolic optimization, sleep interventions, mental health, and menopausal care, ensuring that patient plans are safe, evidence-based, and personalized.

You will learn:

• Foundational goals for obesity care that prioritize reducing visceral and ectopic fat, preventing complications, preserving muscle, and improving quality of life.
• The bidirectional physiology between adiposity and cardiometabolic syndrome, including inflammation, insulin resistance, vascular remodeling, and autonomic stress.
• Outcomes from GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) in reducing cardiovascular events, improving HFpEF, and advancing sleep apnea care.
• The pathophysiology and management of MASLD/MASH, with lifestyle, pharmacology, and integrative strategies.
• Sleep health strategies for OSA, including CPAP, weight loss, positional and myofunctional therapies, and integration with structural care.
• Psychiatric and psychosocial considerations—depression, anxiety, trauma, stress—and structured team approaches using CBT, ACT, and mindful practices.
• Menopausal transitions for women ages 40 to 60, with emphasis on estrogen’s role in adiposity distribution, vascular tone, bone health, metabolism, and individualized care options.
• How integrative chiropractic care enhances outcomes through neuro-musculoskeletal optimization, diaphragmatic mechanics, autonomic balance, and joint-friendly movement rehabilitation.
• A stepwise protocol covering diagnostics, goals, nutrition, movement, sleep, medications, devices, and complementary therapies.
• Specialized focus on sarcopenic obesity and midlife muscle preservation: protein targets, leucine thresholds, vitamin D, resistance training, and progressive rehabilitation.

I include real-world clinical observations from my platforms and extensive references to anchor each concept in modern research. This post is designed to be readable, actionable, and deeply informative, helping you understand the “why” behind every recommendation and how integrative chiropractic care fits into a medically directed, collaborative model to achieve durable, patient-centered outcomes.

Our Integrative Team Model in El Paso, Texas: Medical Direction with Chiropractic Integration

I practice at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where we serve patients with complex metabolic, musculoskeletal, and cardiometabolic needs through a multidisciplinary, integrative model standard in functional medicine and injury care clinics.

• Medical Director and Collaborative Physician: Dr. Maria Guadalupe Cardenas, MD

• Credentials: Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933.
• Experience: Over 40 years practicing internal medicine.
• Role: Medical direction for diagnostics, medication decisions, cardiovascular risk stratification, hepatology coordination, sleep referrals, imaging and lab oversight, and safety management for pharmacotherapy (e.g., GLP-1 receptor agonists, dual GIP/GLP-1 agents), antihypertensives, lipid therapies, and menopausal care.

• My Role: Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

• Neuromusculoskeletal assessment and structural care to improve pain, posture, mobility, diaphragmatic mechanics, and autonomic tone.
• Functional medicine applications to identify root causes—metabolic, endocrine, gut, inflammatory, sleep—and design personalized nutrition, movement, sleep, stress management, and supplementation strategies.
• Rehabilitation and personal injury care integrating joint-friendly programs that respect osteoarthritis, tendinopathies, and prior trauma.

• Our Integrated Services:

• Chiropractic care harmonized with internal medicine oversight.
• Functional medicine diagnostics and personalized nutrition plans.
• Rehabilitation and movement prescriptions tailored to pain, capacity, and goals.
• Sleep assessments with OSA screening and CPAP integration.
• Psychiatric support through behavioral therapy referrals and stress-regulation programs.
• Menopausal health planning, including risk-stratified discussions of menopausal hormone therapy (MHT).
• Cardiometabolic optimization through lifestyle and pharmacology with careful monitoring.

This alignment enables us to deliver evidence-based, patient-centered care for obesity and its many complications, ensuring that each aspect—structural, metabolic, cardiovascular, hepatic, sleep, and psychosocial—receives coordinated attention.

Why We Treat Obesity in Midlife: Foundational Goals and Physiologic Rationale

Adults ages 40 to 60 face rising cardiometabolic risks and functional demands. Our foundational goals reflect both outcomes and mechanisms.

• Reduce Adiposity, Not Just Weight
  • We focus on visceral and ectopic fat—including epicardial, pericardial, hepatic, pancreatic, and intramuscular depots—because these fat stores are metabolically active and secrete pro-inflammatory cytokines and adipokines that impair insulin signaling and vascular health.
  • Physiologic rationale:

• Visceral fat elevates TNF-?, IL-6, C-reactive protein (CRP), and dysregulates adipokines like leptin and resistin, undermining insulin pathways (IRS-1/PI3K/Akt), damaging endothelial function, and increasing oxidative stress.
• Ectopic fat around the heart and liver worsens diastolic function, arrhythmogenesis, hepatic insulin resistance, and gluconeogenesis.

• Prevent and Reduce Obesity-Related Complications
  • Conditions: cardiometabolic syndrome, dyslipidemia, hypertension, sleep apnea, MASLD/MASH, osteoarthritis, depression, reduced mobility.
  • Rationale:

• Interlinked physiology means improving adiposity reduces systemic inflammation, normalizes autonomic balance, lowers RAAS activation, and improves vascular compliance.

• Preserve Muscle Mass and Function
  • Sarcopenic obesity—low muscle with high fat—impairs glucose disposal and mobility.
  • Rationale:

• Muscle is a primary glucose sink via GLUT4; preserving and building muscle raises basal metabolic rate and improves glycemic control, balance, and fall risk.

• Enhance Quality of Life
  • Early wins matter: improved energy, pain reduction, better sleep, and mood shifts promote adherence and resilience.
  • Rationale:

• Even 5–10% weight loss produces measurable benefits in glycemic control, blood pressure, sleep, and joint pain, enabling sustainable change.

Evidence-Based Weight Reduction Thresholds and Real-World Outcomes

Clinical trial data and practice-based observations converge around meaningful weight-loss thresholds:

• 2.5–10% reduction:

• Prediabetes: improvements begin around 2.5%, often maximizing near 10%.
• Type 2 diabetes: benefits start near 2.5% and continue through ~15%.
• Why: improved muscle insulin sensitivity, lower hepatic glucose output, and reduced inflammatory burden.

• Around 5%:

• Dyslipidemia: detectable improvements in triglycerides, HDL, and apoB.
• Knee osteoarthritis: pain reduction and function gains around 5%.
• Quality of life: patients commonly report meaningful gains.

• Around 10%:

• Hypertension, sleep apnea, MASLD: consistent improvements often require roughly 10%.
• Why: reduced visceral fat lowers RAAS tone, improves endothelial function, and reduces airway collapsibility.

• > 15%:

• Type 2 diabetes remission signals, cardiovascular outcomes, and HFpEF symptom reductions increase at higher loss magnitudes—often supported with GLP-1 and dual agonist therapies.

In our clinic, these thresholds align with patient-reported outcomes when coupled with structured movement, sleep optimization, integrative manual therapy, and medical oversight.

Cardiometabolic Syndrome in Midlife: Bidirectional Mechanisms That Matter

One out of three adults has cardiometabolic syndrome—an interlocking cluster of dysglycemia, dyslipidemia, hypertension, and central obesity. Understanding the bidirectional physiology helps us design effective care.

• Adipose Tissue as an Endocrine Organ
  • Adipocytes release cytokines, adipokines, and free fatty acids that alter systemic physiology.
  • Mechanisms:

• Hepatic insulin resistance increases gluconeogenesis, elevates fasting glucose, and boosts VLDL secretion.
• Muscle insulin resistance reduces glucose uptake via interference with IRS-1/PI3K/Akt signaling and mitochondrial function.

• Vascular and Autonomic Consequences

• Inflammatory signals reduce nitric oxide bioavailability, increasing vasoconstriction and vascular resistance.
• Leptin and sleep disruption can elevate sympathetic tone, raising blood pressure and cardiac load.

• Screening Essentials

• Blood pressure, waist circumference, body composition (DXA or bioimpedance), fasting lipids, fasting glucose, A1C.
• Select imaging: coronary artery calcium (CAC) scoring in appropriate risk contexts.
• Psychosocial evaluation: stress, depression, trauma, and behavioral barriers that affect adherence.

How Integrative Chiropractic Care Fits Into Cardiometabolic Management

Chiropractic care addresses neuro-musculoskeletal mechanics and autonomic balance—often overlooked yet pivotal in cardiometabolic health.

• Neuro-Musculoskeletal Optimization

• Improving thoracic mobility, rib mechanics, and diaphragmatic excursion reduces dyspnea, enhances ventilation, and indirectly supports sleep quality and exercise tolerance.
• Better spinal mechanics reduce pain and sympathetic overdrive, facilitating consistent moderate-intensity

• Autonomic Regulation

• Gentle manual therapies and mobilizations combined with breathing coaching can shift toward parasympathetic predominance.
• Why: increased vagal tone lowers heart rate, improves baroreflex sensitivity, and reduces vascular tone—complementing antihypertensives and stress interventions.

• Movement as Medicine

• Individualized exercise plans respect joint limitations, osteoarthritis, tendinopathies, and injury history.
• Progressive resistance training preserves muscle and bone, improving insulin sensitivity and metabolic flexibility.

• Clinical Synergy

• Chiropractic care, synchronized with medical oversight, metabolic therapies, sleep strategies, and mental health support, amplifies outcomes and improves adherence.

Cardiovascular Disease in Obesity: From Sick Fat to Hemodynamics

Obesity drives cardiovascular disease through multiple intertwined mechanisms:

• Epicardial and Pericardial Fat

• Cytokine-rich depots adjacent to the myocardium and coronary arteries promote local inflammation, fibrosis, diastolic dysfunction, and arrhythmias.
• Associations: atrial fibrillation risk, atherosclerotic progression.

• Mechanical and Hemodynamic Stress

• Larger body mass increases blood volume and cardiac output, altering ventricular filling pressures and raising HFpEF risk—especially with hypertension and OSA.

• Systemic Inflammation

• Elevated CRP, IL-6, and TNF-? reduce nitric oxide availability, increase oxidative stress, and trigger microvascular dysfunction.

• Neurohormonal and Metabolic Dysregulation

• RAAS activation, sympathetic overdrive, and insulin resistance create a pro-hypertensive, pro-atherogenic milieu.

• Clinical Implication

• Reducing visceral and ectopic fat attenuates pathophysiologic drivers of cardiovascular disease—this is not cosmetic; it is cardioprotection.

Evidence Spotlight: GLP-1 Receptor Agonists and Dual Agonists in Cardiovascular Outcomes

Modern trials confirm that treating obesity reduces major adverse cardiovascular events (MACE) and improves HFpEF symptom burden.

• Semaglutide and MACE Reduction

• Adults> 45 with overweight/obesity and cardiovascular risk receiving weekly semaglutide saw ~20% relative risk reduction in MACE versus placebo.
• Interpretation: obesity treatment via GLP-1 receptor agonist therapy offers direct cardiovascular risk reduction in addition to weight and glycemic improvements.
• Evidence: SELECT trial findings support weight-centric cardioprotection.

• HFpEF Symptom Improvement

• The STEP-HFpEF trial demonstrated that semaglutide improved heart failure symptoms, physical limitations, and quality of life through substantial weight loss.
• Complement: Tirzepatide, a dual GIP/GLP-1 agonist, showed reductions in composite cardiovascular death or worsening heart failure and improved health status in HFpEF contexts.

• Mechanisms of Action

• Appetite regulation via central pathways, delayed gastric emptying, improved glucose-dependent insulin secretion, reduced glucagon.
• Downstream effects: weight loss, improved insulin sensitivity, reduced inflammatory tone, better hemodynamic efficiency.

• Clinical Integration

• Under Dr. Cardenas’s oversight, we assess candidacy, contraindications (e.g., history of medullary thyroid carcinoma or MEN2), dosing, monitoring, and endpoints (weight, A1C, BP, lipids).
• Chiropractic and rehab ensure mobility gains, minimize musculoskeletal barriers, and sustain exercise adherence during pharmacotherapy.

Citations:

• SELECT Trial: Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (Provide full APA-7 citation)
• STEP-HFpEF: Semaglutide in Obesity-Related HFpEF (Provide full APA-7 citation)
• Tirzepatide SUMMIT Outcomes in HFpEF (Provide full APA-7 citation)

Hypertension in Obesity: Mechanisms, Targets, and Integrative Care

Hypertension prevalence increases between ages 40 and 60 and strongly correlates with obesity.

• Mechanisms

• Compression and elasticity: increased fat mass reduces vascular elasticity and raises systemic vascular resistance.
• RAAS activation: adipose signals stimulate renin and aldosterone, elevating sodium retention and vasoconstriction.
• Inflammation and autonomic imbalance: cytokines elevate sympathetic activity; OSA amplifies nocturnal surges.
• Data: weight gain associates with incremental systolic BP rise; modest weight loss (3–9%) reduces systolic/diastolic BP by ~3 mmHg.

• Treatment Targets

• Aim for 10–15% weight loss for meaningful BP reductions.
• Nutrition: DASH and Mediterranean patterns emphasizing potassium-rich whole foods, lower sodium, fiber, and healthy fats.
• Exercise:> 150 minutes/week of moderate-intensity exercise plus resistance training for endothelial function and insulin sensitivity.
• Sleep: 7–8 hours nightly; screen and treat OSA with CPAP to blunt sympathetic surges.
• Pharmacology: antihypertensives aligned with comorbidities; monitor and reassess dosing as weight declines.

• Chiropractic Integration

• Thoracic mobility and rib mechanics influence breathing efficiency and autonomic tone.
• Breathing practices enhance parasympathetic activity, supporting BP control and stress resilience.

Citations:

• DASH Diet and Blood Pressure Reduction (Provide full APA-7 citation)
• Mediterranean Diet and Cardiometabolic Health (Provide full APA-7 citation)

Dyslipidemia in Obesity: ApoB-Centric Risk and Lifestyle–Drug Synergy

An apoB-centric view refines risk assessment beyond LDL-C alone.

• Pathophysiology

• Insulin resistance increases hepatic VLDL secretion, elevating triglyceride-rich particles and apoB—reflecting the number of atherogenic lipoproteins.
• Small dense LDL particles increase with dysglycemia and hypertriglyceridemia.

• Diagnostics

• Fasting lipid panel, apoB, and lipoprotein(a) as indicated; ASCVD risk calculators guide statin and adjunctive therapy decisions.

• Treatment Strategy

• Weight reduction (5–15%) lowers apoB and raises HDL.
• Nutrition: Mediterranean-style, high fiber, omega-3 fatty acids, nuts, olive oil; reduce refined carbohydrates.
• Exercise: 150 minutes/week of moderate-intensity activity plus resistance training improves HDL and insulin sensitivity.
• Pharmacology: statins, ezetimibe, PCSK9 inhibitors for high-risk profiles; integrate GLP-1 or tirzepatide for metabolic synergy.

• Chiropractic and Rehab Roles

• Reduce pain and improve mobility to enable regular exercise.

Citation:

• ApoB-Centric Risk Assessment in Dyslipidemia (Provide full APA-7 citation)

Insulin Resistance: The Metabolic Core of Cardiometabolic Disease

Insulin resistance is central to obesity’s cardiometabolic consequences.

• Mechanisms

• Free fatty acids and cytokines disrupt insulin signaling by altering IRS-1 phosphorylation and reducing PI3K/Akt activity.
• Hepatic insulin resistance increases gluconeogenesis and VLDL output; muscle insulin resistance reduces GLUT4-mediated uptake.

• Clinical Features

• Fasting hyperglycemia, elevated A1C, postprandial spikes, fatigue after meals, central adiposity, acrochordons, acanthosis nigricans.

• Interventions

• Weight reduction via nutrient-dense, lower-glycemic patterns and GLP-1 or dual agonists.
• Carbohydrate periodization, adequate protein for muscle preservation, timing carbohydrates around activity.
• Exercise: resistance plus aerobic training enhances GLUT4, mitochondrial function, and metabolic flexibility.
• Sleep: OSA treatment and sleep optimization reduce insulin resistance.

• Chiropractic Support

• Pain reduction and mobility improvements enable training; autonomic balance supports glycemic regulation.

Citations:

• Insulin Resistance Mechanisms in Obesity (Provide full APA-7 citation)
• Exercise and GLUT4, Mitochondrial Function (Provide full APA-7 citation)

Obstructive Sleep Apnea and Sleep Health in Obesity

Sleep profoundly impacts metabolic control and cardiovascular risk.

• OSA in Obesity

• Peripharyngeal fat increases upper airway collapsibility; intermittent hypoxia triggers sympathetic surges, elevating BP and oxidative stress.

• Screening

• STOP-BANG, Epworth Sleepiness Scale, overnight oximetry; polysomnography for diagnostic confirmation.
• Daytime sleepiness, snoring, witnessed apneas, nocturia, and morning headaches are clinical clues.

• Management

• CPAP improves oxygenation, stabilizes BP, and reduces sympathetic tone.
• Weight loss (~10%) reduces OSA severity; myofunctional therapy and positional strategies can help; minimize alcohol before sleep.
• Sleep hygiene: keep a consistent schedule, keep the room dark and cool, and limit late caffeine and screen exposure.

• Chiropractic Integration: Improving t
• horacic and cervical mobility supports ventilatory efficiency.
• Diaphragmatic training and rib cage mobilization enhance breathing mechanics and calm autonomic arousal.

Citations:

• Obstructive Sleep Apnea and Cardiometabolic Risk (Provide full APA-7 citation)
• Tirzepatide for OSA after SURMOUNT-OSA (Malhotra et al., 2024)

Hepatic Health: MASLD/MASH (formerly NAFLD/NASH) in Obesity

The liver is a metabolic hub disrupted by adiposity and insulin resistance.

• Pathophysiology

• Hepatic insulin resistance increases de novo lipogenesis, reduces fatty acid oxidation, and promotes ectopic fat accumulation; mitochondrial stress drives inflammation and fibrosis (MASH).

• Diagnostics

• ALT/AST trends (often ALT > AST in MASLD), GGT, fasting insulin, HOMA-IR; non-invasive fibrosis scores (FIB-4, NAFLD fibrosis score).
• Imaging: ultrasound, elastography (FibroScan), MRI-PDFF for precise fat quantification.

• Interventions

• Weight loss of ~7–10% reduces steatosis; ~10% may improve inflammation; ~15% may affect fibrosis in some.
• Diet: Mediterranean pattern with reduced fructose and high fiber; omega-3 fats; reduced saturated and trans fats.
• Exercise: aerobic and resistance training improve hepatic fat handling independent of weight loss.
• Pharmacology: GLP-1 and dual agonists demonstrate steatosis benefit; hepatology referral for advanced fibrosis (e.g., resmetirom for MASH with F2–F3).
• Supplements under medical oversight: Vitamin E (select non-diabetic MASH), omega-3s, insulin sensitizers where appropriate.

• Chiropractic Role

• Movement adherence, pain reduction, and diaphragmatic motion improve comfort and enable regular exercise, indirectly supporting hepatic venous return and visceral mobility.

Citations:

• MASLD/MASH Pathophysiology and Interventions (Provide full APA-7 citation)

Osteoarthritis, Mobility, and Musculoskeletal Health in Obesity

Obesity increases joint loads and inflammatory mediators affecting cartilage and synovium.

• Mechanisms

• Elevated compressive forces accelerate cartilage wear; cytokines increase synovial inflammation and pain.

• Weight Loss Benefits

• ~5% reduction often yields notable pain and function improvements.
• Strength training stabilizes joints and reduces pain.

• Interventions

• Low-impact exercise: cycling, swimming, elliptical, aquatic therapy.
• Joint-friendly progression emphasizing biomechanics, posture, and core stability.
• Manual therapy: adjustments and soft tissue work for mobility and pain reduction.

• Chiropractic Integration

• Spinal and extremity care, movement coaching, ergonomic training tailored to osteoarthritis limitations.

Citation:

• [STEP 9: Semaglutide in knee osteoarthritis with obesity] (Full publication details pending; conference data presented; see Bliddal et al., 2024 reference note)

Psychiatric and Psychosocial Considerations in Obesity Care

Midlife obesity frequently coexists with depression, anxiety, trauma, and chronic stress—each elevating cortisol, inflammatory tone, and appetitive drive.

• Assessment

• Depression (PHQ-9), perceived stress (PSS), trauma history, emotional eating behaviors, social isolation, workplace pressures, caregiving burdens.
• Weight stigma and shame impede care and erode trust—clinician empathy and person-first language are essential.

• Why It Matters

• Chronic stress dysregulates the HPA axis, increases cortisol and ghrelin, impairs prefrontal control, and amplifies reward-seeking in hyper-palatable food environments, fueling emotional eating.

• Interventions

• Behavioral therapy: CBT, ACT, mindful eating, motivational interviewing.
• Group support and peer accountability reduce isolation and strengthen adherence.
• Sleep and stress programs, breath-focused relaxation, and autonomic regulation enrich resilience.
• Chiropractic contribution: pain relief and physical empowerment reduce depressive symptoms; breath and mobility sessions calm autonomic activation.

Citations:

• Depression and Obesity in the U.S. Adult Population (Pratt & Brody, 2014)

Menopausal Health for Women Ages 40 to 60 with Obesity

Menopause reorients adiposity distribution, cardiometabolic risk, and musculoskeletal health.

• Estrogen’s Role

• Estrogen maintains vasodilatory tone, insulin sensitivity, and favorable fat distribution (gynoid/higher gluteofemoral mass).
• Decline increases visceral fat, raises LDL, reduces HDL, and alters vascular reactivity; hot flashes, sleep disruption, mood changes, and central adiposity are common.

• Interventions

• Nutrition: higher protein for muscle retention (addressing partial anabolic resistance), fiber for glycemic control, phytonutrients for vascular health.
• Exercise: resistance training prioritized for bone and muscle; moderate aerobic exercise for cardiometabolic health.
• Sleep: treat insomnia and OSA; sleep hygiene and relaxation practices.
• Medical therapy: individualized discussions on MHT under internal medicine oversight, balancing benefits and risks based on cardiovascular and cancer profiles; non-hormonal VMS options when indicated.
• Supplements under supervision: vitamin D, magnesium, omega-3s.

• Chiropractic Integration

• Address musculoskeletal pain, posture, pelvic mechanics; enable exercise adherence despite joint or soft tissue discomfort.
• Breathing and mobility may reduce vasomotor symptom intensity via improved autonomic balance.

Citations:

• The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS, 2022)
• Association of Mid-life Weight Gain with the Menopausal Transition (Karvonen-Gutierrez & Kim, 2016)
• Vasomotor Symptoms and Sleep (Thurston et al., 2019)

The Four-Pillar Approach: Nutrition, Exercise, Sleep, and Risk Optimization

Our comprehensive care strategy integrates lifestyle pillars with pharmacotherapy and manual-rehab care.

• Nutrition Therapy

• Mediterranean/DASH patterns emphasizing whole foods, lean proteins, legumes, vegetables, fruits, whole grains, nuts, seeds, and healthy oils.
• Carbohydrate quality, timing, high fiber, and reduced added sugars.
• Personalized macro distribution aligned to insulin sensitivity and activity level.

• Exercise Prescription

• 150 minutes/week moderate-intensity aerobic activity plus resistance training 2–3 days/week.
• Flexibility and balance training for fall prevention and functional agility.

• Sleep Optimization

• 7–8 hours nightly; OSA screening and CPAP adherence.
• Sleep hygiene and circadian alignment support metabolic and autonomic health.

• Risk Factor Management

• Hypertension: medication optimization with weight-based adjustments; lifestyle synergy.
• Dyslipidemia: statins per risk, apoB targets for precision risk reduction.
• Glycemic control: GLP-1 or dual agonists; consider metformin when appropriate.

• Chiropractic–Rehab Integration

• Manual therapy for pain relief, mobility gains, and autonomic regulation via breath and rib mechanics.
• Joint-friendly movement coaching and progressive plans aligned with structural realities.

Citations:

• Mediterranean Diet and Cardiometabolic Health (Provide full APA-7 citation)
• DASH Diet and Blood Pressure Reduction (Provide full APA-7 citation)

Practical Clinic Workflow in Our Multidisciplinary Model

Under Dr. Cardenas’s medical direction, we follow an integrated workflow to ensure safe, consistent, high-quality care.

• Intake and Risk Mapping

• Comprehensive history, psychosocial review, medications.
• Vitals, waist circumference, body composition, targeted physical exam.

• Diagnostics

• Labs: fasting glucose, A1C, fasting insulin, lipid profile, apoB, lipoprotein(a), liver enzymes, hs-CRP (as indicated).
• Imaging: CAC scoring in selected patients; hepatic elastography for suspected MASLD/MASH.
• Sleep testing: OSA screening; polysomnography when indicated.

• Care Team Conference

• Collaborative review: internal medicine, chiropractic, rehabilitation, nutrition/functional medicine.
• Personalized plan with phased goals, metrics, and milestone dates.

• Implementation

• Achievable targets (e.g., 5% weight loss), progressive movement, sleep stabilization.
• Pharmacotherapy initiation under MD oversight; education on mechanism, expectations, side-effect management.

• Monitoring

• Follow-ups tracking weight, waist, BP, labs, sleep adherence, functional capacity.
• Therapy adjustments based on response and tolerance.

• Reinforcement and Adaptation

• Behavioral supports, group programs, peer accountability.
• Escalation for non-responders: advanced therapies, second-line medications, specialty referrals.

Why Integrative Care Works: Synergies That Restore Health

Combining chiropractic care with internal medicine oversight amplifies outcomes:

• Pain reduction enables movement; movement improves insulin sensitivity, vascular function, and mood.
• Autonomic regulation enhances BP control and stress resilience; reduced stress decreases emotional eating and stabilizes sleep.
• Medical therapies (GLP-1 RA, tirzepatide) drive weight loss and cardiometabolic improvements; structural care enhances adherence to exercise prescriptions and daily activity.
• Functional medicine context addresses nutrition quality, sleep, gut health, inflammation, and micronutrients—accelerating durable clinical changes.

Case-Based Reflections from Our Practice

We observe consistent patterns in our El Paso clinic that highlight integrative strategy benefits:

• Case: 52-year-old with central obesity, hypertension, dyslipidemia, poor sleep

• After 12 weeks of GLP-1 therapy, DASH-style nutrition, thoracic mobilization, and CPAP adherence: improved energy, reduced BP, better exercise tolerance; apoB decreased; waist circumference reduced.

• Case: 58-year-old male with HFpEF and knee osteoarthritis

• Combined semaglutide-driven weight loss, aquatic therapy, low-impact resistance training, knee-focused manual therapy: reduced dyspnea, improved functional capacity, lower symptom burden—consistent with STEP-HFpEF

• Case: 46-year-old peri-menopausal woman with emotional eating

• Behavioral therapy, stress management, breathing practices, and consistent chiropractic care: pain and sleep improved; personalized protein targets and resistance training maintained lean mass while reducing visceral fat; risk-based MHT discussion under Dr. Cardenas’s oversight supported symptom control.

These cases illustrate how tailored, integrative care reduces ectopic fat, improves insulin sensitivity, stabilizes hemodynamics, and restores function.

Physiologic Rationale Behind Key Interventions

• GLP-1 Receptor Agonists

• Central satiety via hypothalamic pathways, delayed gastric emptying, improved beta-cell responsiveness, reduced glucagon.
• Downstream: decreased caloric intake, improved glycemic control, reduced lipotoxicity, lower systemic inflammation.

• Dual GIP/GLP-1 Agonists (Tirzepatide)

• Synergistic incretin effects yield greater weight loss and insulin sensitization; clinical signals suggest HFpEF and lipid improvements.

• Resistance Training

• Increases GLUT4 translocation and mitochondrial density; raises resting metabolic rate; preserves bone density; reduces fall risk.

• Mediterranean/DASH Nutrition

• Polyphenols support endothelial function; omega-3 fatty acids reduce triglycerides and inflammation; fiber stabilizes glycemic excursions and supports microbiome health.

• Sleep Optimization

• Stabilizes leptin and ghrelin, reduces cortisol, improves insulin sensitivity and BP regulation; CPAP reduces intermittent hypoxia and sympathetic surges.

• Chiropractic and Manual Therapy

• Reduces nociception, modulates autonomic tone, enhances mobility and breathing mechanics; increases exercise adherence and lowers barriers to lifestyle change.

Citations:

• Mediterranean Diet and Cardiometabolic Health (Provide full APA-7 citation)
• DASH Diet and Blood Pressure Reduction (Provide full APA-7 citation)
• Exercise and GLUT4, Mitochondrial Function (Provide full APA-7 citation)

Safety, Dosing, and Monitoring Under Internal Medicine Oversight

Medical safety is paramount; Dr. Cardenas’s oversight ensures best-practice protocols:

• GLP-1 RA Initiation

• Gradual titration to mitigate GI side effects; screen for contraindications (e.g., medullary thyroid carcinoma, MEN2).
• Monitor: weight, glucose, A1C, BP, lipids, adverse effects.

• Tirzepatide Considerations

• Titration principles similar to GLP-1; anticipate robust weight loss and metabolic improvements; track HFpEF symptoms where applicable.

• Statins and Lipid-Lowering Drugs

• Baseline and follow-up lipids; consider apoB targets for precision risk reduction; monitor transaminases as indicated.

• Antihypertensives

• Reassess dosing as weight reduces; incorporate home BP monitoring.

• Sleep Therapy

• CPAP adherence and pressure optimization; track daytime function and ESS scores.

Patient-Centered Plans: Communication, Motivation, and Staged Goals

Patients succeed when they understand the “why” behind each intervention:

• We explain mechanisms in plain, actionable terms:

• “Visceral fat sends inflammatory signals that raise blood pressure and impair insulin.”
• “Better sleep reduces stress hormones and helps your metabolism function properly.”

• We set staged targets:

• Early: 5% weight loss with improvements in energy and sleep.
• Medium: 10–15% for hypertension, OSA, and liver improvements.
• Long-term: maintenance with muscle preservation.

• We emphasize small wins:

• Waist circumference, step counts, CPAP hours, resistance sessions, energy ratings.

• We normalize setbacks:

• Continuous learning and iteration; supportive rapport; adjustments that respect patient preferences and capacity.

Coordinating Care in a Multidisciplinary Framework

• Weekly Team Review

• Aligns chiropractic, medical, nutrition, rehab, and behavioral plans; ensures safety and consistency.

• Digital Support

• Remote BP, weight, and activity monitoring; secure messaging for timely adjustments.

• Community Resources

• Group movement and stress-reduction classes; peer support networks to reduce isolation and enhance adherence.

Metrics That Matter: Defining Success Beyond the Scale

We track concrete outcomes across physiologic and functional domains:

• Adiposity Reduction

• Waist circumference, DXA or validated bioimpedance (truncal fat changes).

• Metabolic Improvements

• A1C, fasting insulin, HOMA-IR, apoB, triglycerides, HDL.

• Cardiovascular Risk

• CAC trajectories (selected patients), BP curves, symptom scales (HFpEF).

• Sleep and Function

• CPAP adherence data, Epworth Sleepiness Scale, six-minute walk tests.

• Quality of Life

• Patient-reported pain, fatigue, mood, work productivity, social engagement.

Bringing It Together: A Sample Integrated Protocol with Specific Dates

Anchored to our content creation date, we use specific timelines to enhance accountability.

• Baseline (by 2026-08-17)

• Labs: fasting glucose, A1C, lipids, apoB; BP, waist, body composition; OSA screen; psychosocial assessment.

• Month 1–3 (by 2026-09-17 through 2026-11-17)

• Nutrition: Mediterranean/DASH with protein optimization and fiber emphasis.
• Movement: resistance training 3 days/week as tolerated; moderate cardio 2 days/week; dedicated breathing work.
• Sleep: hygiene and CPAP initiation/optimization if OSA is confirmed.
• Medications: initiate GLP-1 RA or tirzepatide if indicated; manage antihypertensives and statins appropriately.
• Chiropractic: weekly sessions targeting thoracic mobility, rib mechanics, pain reduction; progress to functional patterns.

• Month 4–6 (by 2026-12-17 through 2027-02-17)

• Advance exercise intensity safely; integrate intervals where tolerable.
• Reassess labs; adjust medications; taper antihypertensives as appropriate with BP improvements.

• Month 6–12 (by 2027-02-17 through 2027-08-17)

• Maintain weight loss; emphasize muscle building and consistency.
• Continue behavioral support; refine sleep and stress practices; update metrics.

Insulin Resistance and Dysglycemia: Early Detection and Targeted Care

Insulin resistance can precede type 2 diabetes by a decade or more, creating a critical intervention window.

• Evaluation

• Fasting insulin and glucose; HOMA-IR calculation; A1C; lipid panel (triglycerides, HDL; apoB when indicated).

• Intervention Strategy

• Weight reduction as cornerstone; lower refined carbohydrate intake; whole-food emphasis with adequate protein and fiber.
• Pharmacotherapy: Metformin for insulin resistance when appropriate; GLP-1 RA or dual agonists to achieve significant weight loss and glycemic control.

• Supporting Evidence

• Trials demonstrate that aggressive obesity treatment reduces progression from prediabetes to diabetes and improves glycemic control.
• SURMOUNT-1 showed tirzepatide markedly reduced progression to type 2 diabetes and produced substantial weight loss in obesity with prediabetes.
• STEP program trials demonstrated semaglutide’s robust weight loss and high rates of reversion from prediabetes to normoglycemia.

Citations:

• Tirzepatide once weekly for the treatment of obesity (Jastreboff et al., 2022)
• Effect of semaglutide with behavioral therapy on body weight in adults with overweight/obesity (Wadden et al., 2021; STEP 3 principles relevant to STEP 10 prediabetes focus)
• Eight-year weight losses with intensive lifestyle intervention: Look AHEAD (Look AHEAD Research Group, 2014)

Confronting Weight Bias and Building Therapeutic Alliance

A respectful, empathetic environment is essential:

• Person-First Language

• “Patient with obesity,” not “obese patient”; respect, validation, and trust-building.

• Active Listening and Validation

• Acknowledge biological, genetic, and environmental complexity; partner in co-creating realistic strategies.

• Clinical Impact

• Reducing bias improves adherence, reduces care avoidance, and enhances mental health—a necessary foundation for success.

Sarcopenic Obesity and Midlife Metabolic Health: Protein, Leucine, and Muscle-Centric Care

Sarcopenic obesity arises from low muscle mass and strength concurrent with high fat mass, undermining metabolic health and function.

• Why It Matters

• Increased inflammatory mediators from adipose tissue accelerate muscle breakdown; diminished muscle lowers basal metabolic rate and activity tolerance—creating a self-reinforcing cycle.

• Prevalence and Risk

• Significant rates among adults 20–60, rising beyond 60; increased risk in Mexican American women over 60 and in individuals with prediabetes, diabetes, MASLD, post-bariatric states, and chronic illness.

• Reversal Strategy

• Evidence-based nutrition, progressive physical activity, targeted supplementation, medical oversight, and integrative chiropractic care.

• Protein Targets and Leucine Thresholds

• Practical range: 0–1.5 g/kg/day in supervised contexts; per-feeding leucine triggers (~2–3 g leucine, commonly achieved with 25–35 g high-quality protein).
• Meal spacing: protein feedings every 3–4 hours to sustain muscle protein synthesis (MPS), countering anabolic resistance.
• Vitamin D repletion supports neuromuscular function; whey shakes around training provide rapid digestibility and leucine density.

• Resistance Training

• Two or more sessions/week when tolerated; start with one session focused on compound movements and core stabilization; progressive loading improves MPS, mitochondrial biogenesis, and function.

• Carbohydrate Reduction

• Lower refined carbohydrate intake reduces insulin exposure and supports visceral fat mobilization; time carbohydrates around activity if performance needs dictate.

• Chiropractic Integration

• Manual therapy reduces pain and restrictions; neuromuscular re-education enhances motor control and stability; ergonomic and gait coaching protects joints and enables training progression.

Citations:

• Evidence-based recommendations for optimal dietary protein intake in older people (Bauer et al., 2013)
• Resistance training and sarcopenia reversal (Provide full APA-7 citation)
• Physical activity guidelines for adults (Provide full APA-7 citation)
• DEXA body composition analysis and clinical utility (Provide full APA-7 citation)

Case Study: Maggie—Perimenopause, Prediabetes, and Abdominal Adiposity

• Patient Profile

• 53-year-old CPA; perimenopausal symptoms (hot flashes, insomnia, anxiety); BMI increase during perimenopause; fasting insulin elevated; A1C 5.8 (prediabetes); waist circumference increased.

• Goals

• Reduce weight and central adiposity; address prediabetes; improve sleep and vasomotor symptoms; enhance functional capacity and mood.

• Plan

• Nutrition: carbohydrate reduction, protein target ~90–100 g/day with 3–4-hour spacing; minimize ultra-processed foods.
• Alcohol: taper nightly wine to improve sleep and insulin sensitivity via motivational interviewing.
• Physical Activity: maintain daily walks; introduce higher-intensity cardio; begin one resistance session/week, increasing as tolerated.
• Pharmacotherapy: metformin ER 500 mg (off-label for prediabetes under MD oversight) with slow titration; reassess gabapentin efficacy; MHT as appropriate per risk.
• Sleep: cognitive behavioral therapy for insomnia, sleep hygiene.
• Chiropractic: thoracic mobility, pelvic alignment, core stability, soft tissue interventions; breathing training for autonomic balance.
• Functional medicine: check vitamin D and magnesium; add omega-3s; align circadian rhythm.
• Follow-up: track body composition, strength, glycemic metrics; adjust training and medications accordingly.

Case Study: Maria—Class II Obesity, Diabetes, Osteoarthritis, Post-MI Risk, Sarcopenia

• Patient Profile

• 59-year-old health executive; prior MI; type 2 diabetes; hypertension and dyslipidemia; bilateral knee osteoarthritis; mild depression; body fat ~58%; low muscle mass; visceral adipose tissue 3.4 L; waist 43.5 inches.

• Goals

• Reduce weight and visceral fat; improve body composition; optimize diabetes and triglycerides; improve mobility; reduce cardiometabolic risk.

• Plan

• Nutrition: high-quality protein, fiber-rich vegetables, low-glycemic fruits; leucine-rich feedings every 3–4 hours; Mediterranean pattern to support MASLD improvement.
• Referrals: physical therapy for sarcopenia and knee OA; orthopedic evaluation for injections or surgical candidacy if needed.
• Medications: add semaglutide for obesity and cardioprotection post-MI; taper insulin as control improves; monitor triglycerides, HDL, liver enzymes.
• Physical Activity: PT-directed strengthening and mobility; low-impact cardio (swimming, stationary cycling).
• Chiropractic: assess joint biomechanics, pelvic/lumbar alignment; manual therapy for gait and core stabilization.
• Functional medicine: anti-inflammatory nutrition, omega-3s, vitamin D repletion, magnesium for sleep and metabolic health.
• Psychosocial: address bias concerns; create safety and dignity in care; realistic goals; celebrate functional wins.
• Follow-up: track composition, visceral fat markers, strength, A1C, triglycerides, liver enzymes, BP; adjust GLP-1 dosing and PT progression.

Clinical Observations: Real-World Patterns and Practical Adjustments

In my daily practice, I see consistent themes that inform care:

• Pain and stiffness are common barriers; manual therapy and joint-friendly exercise (aquatic, cycling) unlock capacity for aerobic and resistance training.
• Sleep improvements via CPAP and hygiene often produce rapid gains in energy, appetite regulation, and mood.
• Protein adequacy and leucine timing enhance satiety and MPS, helping patients sustain deficits without hunger; vitamin D and magnesium support neuromuscular and sleep functions.
• GLP-1 or tirzepatide enable insulin tapering, improving weight loss trajectories and motivation.

Clinical insights and case narratives are documented on my platforms:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

Stepwise Care and Timelines: Building Success in Measurable Stages

We emphasize progressive, achievable steps:

• Baseline: body composition, strength, gait, posture, glucose, insulin, lipids, sleep.
• Initial actions: per-feeding protein triggers, reduced refined carbs, low-impact cardio, one resistance session, manual therapy.
• Early wins: better sleep, less pain, improved energy.
• Progression: increased cardio minutes, second resistance session, load increments.
• Pharmacotherapy: metformin or GLP-1 initiation under oversight; insulin tapering as warranted.
• Integration: PT progressions, supplementation, ergonomic coaching.
• Tracking: DXA or bioimpedance comparisons; waist circumference; labs.
• Refinement: macro adjustments, feeding windows, training intensity, recovery routines.

Timelines anchored to dates help accountability and focus:

• By 2026-09-17: establish protein spacing; complete three weeks with one weekly resistance session.
• By 2026-10-17: reach 120 minutes of moderate cardio weekly; consider GLP-1/metformin adjustments.
• By 2026-11-17: repeat body composition assessment; evaluate changes in waist, strength, energy.
• By 2026-12-17: maintain two weekly resistance sessions; review medication adjustments and sleep improvements.

Removing Barriers: Pain, Bias, Access, and Adherence Support

• Pain and mobility limitations: we deploy manual therapy, PT, and tailored exercise to sustain momentum.
• Bias in healthcare: we advocate for thorough evaluations and equitable treatment—especially for women and individuals with obesity.
• Access to diagnostics: we help patients locate DXA or cost-effective alternatives; we use body composition data to motivate and tailor plans.
• Adherence: we leverage coaching, small wins, social support, digital monitoring, and transparent communication to sustain change.

Continuous Learning and Evidence-Based Methods

We remain current with research across protein metabolism, resistance training, cardiometabolic therapies, sleep medicine, hepatic care, and functional medicine. We hyper-focus on measurable outcomes—stronger grip, faster sit-to-stand, reduced waist circumference, lower A1C and apoB, improved triglycerides, better sleep, and higher quality of life.

Practical Tips You Can Start Today

• Prioritize high-quality protein at each meal; consider a whey shake with leucine and vitamin D.
• Space protein feedings every 3–4 hours to support MPS and satiety.
• Replace ultra-processed foods with whole proteins, vegetables, and low-glycemic fruits.
• Add a slightly higher-intensity cardio session weekly beyond your usual walk.
• Begin one resistance training session per week focusing on form and core stability.
• Improve sleep hygiene: consistent bedtime, reduced evening alcohol, cool, dark bedroom.
• For knee pain, prefer cycling or swimming to build cardio capacity with minimal joint stress.
• Practice diaphragmatic breathing daily to enhance autonomic balance and stress control.

Conclusion: Integrative Care as the Standard for Midlife Obesity and Metabolic Health

Obesity in adults ages 40 to 60 is a multisystem disease requiring comprehensive, collaborative care. By integrating internal medicine oversight with chiropractic care, functional medicine, rehabilitation, and modern pharmacotherapy, we address fundamental drivers—visceral adiposity, inflammation, insulin resistance, autonomic imbalance—and help patients achieve meaningful, sustainable health.

We see day after day how aligning medical direction with structural optimization creates conditions for success: less pain, better sleep, consistent movement, stronger hearts, healthier livers, improved mood, and higher quality of life. The science affirms it; our patients feel it; and together, with careful monitoring and compassionate teamwork, we make it real.

References

• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

• Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831

• Look AHEAD Research Group. (2014). Eight-year weight losses with an intensive lifestyle intervention: The Look AHEAD study. Obesity, 22(1), 5–13. https://doi.org/10.1002/oby.20662

• Malhotra, A., Grunstein, R. R., Cheng, S. T., Gilmartin, T., Ramirez, G., Holzer, E., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2404881

• Pratt, L. A., & Brody, D. J. (2014). Depression and obesity in the U.S. adult household population, 2005–2010. NCHS Data Brief, no. 167. National Center for Health Statistics. https://www.cdc.gov/nchs/products/databriefs/db167.htm

• The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf

• Karvonen-Gutierrez, C., & Kim, C. (2016). Association of mid-life weight gain with the menopausal transition. Women’s Midlife Health, 2(1), 1–8. https://doi.org/10.1186/s40695-016-0018-8
• Thurston, R. C., Chang, Y., Buysse, D. J., Hall, M. H., & Matthews, K. A. (2019). Vasomotor symptoms and sleep. Sleep, 42(9), zsz128. https://doi.org/10.1093/sleep/zsz128
• [ApoB-centric risk assessment in dyslipidemia] (https://www.jacc.org/)
• [Obstructive sleep apnea and cardiometabolic risk] (https://www.thelancet.com/)
• [Mediterranean diet and cardiometabolic health] (https://www.bmj.com/)
• [DASH diet and blood pressure reduction] (https://www.nejm.org/)
• Insulin resistance mechanisms in obesity
• Exercise and GLUT4, mitochondrial function
• MASLD/MASH pathophysiology and interventions
• Resistance training and sarcopenia reversal
• Physical activity guidelines for adults
• DEXA body composition analysis and clinical utility
• Personal Injury Doctor Group: Clinical observations and multidisciplinary care integration
• Alex Jimenez LinkedIn: Professional insights on integrative care

 

SEO tags: integrative obesity care, midlife obesity, ages 40 to 60, cardiometabolic syndrome, GLP-1 semaglutide, tirzepatide, HFpEF, hypertension, dyslipidemia, insulin resistance, MASLD, MASH, sleep apnea, CPAP, menopause and obesity, vasomotor symptoms, protein leucine, sarcopenic obesity, resistance training, Mediterranean diet, DASH diet, apoB, visceral fat, autonomic balance, diaphragmatic mechanics, chiropractic care, internal medicine oversight, functional medicine, rehabilitation, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso Texas, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, evidence-based obesity treatment, quality of life, personal injury care, HOMA-IR, DEXA body composition